Each patient needs to weigh the benefits and risks of genetic testing for melanoma and have someone who can take the time to explain everything, including insurance risks, said Sancy Leachman, MD, PhD, professor and chair in the Department of Dermatology and director of the Melanoma Research Program at the Knight Cancer Institute at Oregon Health and Science University.
Each patient needs to weigh the benefits and risks of genetic testing for melanoma and have someone who can take the time to explain everything, including insurance risks, said Sancy Leachman, MD, PhD, professor and chair in the Department of Dermatology and director of the Melanoma Research Program at the Knight Cancer Institute at Oregon Health and Science University.
Transcript
After a patient gets a genetic test to understand their risk for developing melanoma, what should the next steps be for them?
It needs to be tailored for the individual. I send all of my patients who are candidates for testing to a genetic counselor, because I feel like they can spend the time to sit with them—they'll spend an hour or 2 hours sometimes—discussing the pros and the cons of getting the genetic testing, and whether or not that's something they want to go through at this time or not. They'll spend time finding out if their insurance will cover it after the testing or not, or if they're going to have to pay out of pocket. They spend the time really going through deeply through their pedigree, so that they can identify not just the melanoma genes, but let's say they had breast cancer or colon cancer, they want to put the genes that are responsible for those sort of patterns of cancer in the panel that gets tested, and they can help to identify those specific genes that need to be for sure included in the panel. That takes a lot of time.
I think that the patient is best served by having a person who can devote that time to doing a really thorough job with that and talking about the risks of insurance. In the United States, we've got GINA, the Genetic Information Nondiscrimination Act. Most states also have a nondiscrimination act. Those are very important to make sure that if you do get genetic testing, that you don't have to worry about your health insurance or your employment. It's illegal to fire you or cancel your health insurance. You can't have that happen. But you can have a problem getting life insurance or disability insurance, because those are considered more of the luxury items. They don't fall under the GINA or the nondiscrimination act for the state.
You need to make sure that you know those risks and that the knowledge that you're getting, is going to be worth it. I think that the next step is to really consider that, and to have somebody that can sit and talk to you about it and make sure that you understand what the real risks and benefits are. And I haven't talked about the benefits, but I think those are just as important. And I do think in many cases, the benefits do outweigh the risks there.
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Margin Status Likely Not a Factor in STS Recurrence
May 10th 2024The optimal negative margin required following surgical resection and perioperative radiotherapy for extremity soft tissue sarcoma (STS) remains up for debate, with investigators of a new study using Union for International Cancer Control classification to define resection margin.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More